Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for Interleukin 2 Receptor alpha
Most Correlated Studies
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
- Drug target sets for approved compounds
Most Relevant Literature
- Whole exome sequencing identified a novel splice donor site variant in interleukin 2 receptor alpha …
- Immunosuppressive effects of triptolide via interleukin-2/receptor signaling.
- Non-IL-2-blocking anti-CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic ef…
- CD25: A potential tumor therapeutic target.
- Distinct use of super-enhancer elements controls cell type-specific CD25 transcription and function.
Most Relevant Clinical Trials
- BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage
- Interleukin and Autoantibodies in Myasthenia Gravis.
- Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis
- Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in H…
- Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interle…
